Immune Thrombocytopenia (ITP) Therapy

Coverage is for treatment of primary ITP when there is severe bleeding, platelet count ≤30 x10^9/L (especially with bleeding risk factors), need for rapid platelet response, preparation for high‑bleeding‑risk procedures, or persistent/chronic disease >6 months. First-line therapy is corticosteroids; IVIG or anti‑D (adult, Rh‑positive, nonsplenectomized) may be first‑line for rapid response, steroid contraindication, or steroid nonresponse. Second‑line options (splenectomy, TPO‑RAs, rituximab) require documented lack of response to at least one first‑line therapy and documentation of bleeding risk, with additional requirements for splenectomy such as pre‑op vaccinations and patient informed consent.

"Treatment is indicated for Primary Immune Thrombocytopenia (ITP) when there is severe ITP with bleeding symptoms."

Sign up to see full coverage criteria, indications, and limitations.